Cargando…

Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients

Nonalcoholic fatty liver disease (NAFLD) is well described as a common cause of chronic liver disease, mostly in the obese population. It refers to a spectrum of chronic liver disease that starts with simple steatosis than progresses to nonalcoholic steatohepatitis and cirrhosis in patients without...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yousef, Mohamad H, Al Juboori, Alhareth, Albarrak, Abdulmajeed A, Ibdah, Jamal A, Tahan, Veysel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561430/ https://www.ncbi.nlm.nih.gov/pubmed/28868179 http://dx.doi.org/10.4291/wjgp.v8.i3.100

Ejemplares similares

Coffee: The magical bean for liver diseases
por: Heath, Ryan D, et al.
Publicado: (2017)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Elderly donor graft for liver transplantation: Never too late
por: Chela, Harleen, et al.
Publicado: (2017)

Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?
por: Devi, Jalpa, et al.
Publicado: (2022)

Epidemiology, determinants, and management of AIDS cholangiopathy: A review
por: Naseer, Maliha, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease and cardiovascular risk
por: Patil, Rashmee, et al.
Publicado: (2017)

Growing challenge of post-liver transplantation non-alcoholic fatty liver disease
por: Kalogirou, Maria Styliani, et al.
Publicado: (2022)

Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
por: Wong, Carrie R, et al.
Publicado: (2016)

Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Said, Adnan, et al.
Publicado: (2017)

Racial differences in prevalence and severity of non-alcoholic fatty liver disease
por: Bonacini, Maurizio, et al.
Publicado: (2021)

Therapies for non-alcoholic fatty liver disease: A 2022 update
por: Shen, Katie, et al.
Publicado: (2022)

Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease
por: Mato, José M, et al.
Publicado: (2019)

Relationship between non-alcoholic fatty liver disease and coronary heart disease
por: Arslan, Ugur, et al.
Publicado: (2020)

Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome
por: Sheng, Wei, et al.
Publicado: (2022)

Research progress on the mitochondrial mechanism of age-related non-alcoholic fatty liver
por: Wang, Dan, et al.
Publicado: (2023)

Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
por: Chackelevicius, Carla Melisa, et al.
Publicado: (2016)

Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
por: Chen, Hui-Ting, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring
por: Wajsbrot, Natalia Balassiano, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?
por: Mattos, Ângelo Z, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
por: Dietrich, Christoph G, et al.
Publicado: (2023)

Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship?
por: Janota, Barbara, et al.
Publicado: (2023)

Is the 25-year hepatitis C marathon coming to an end to declare victory?
por: Ahmed, Khulood T, et al.
Publicado: (2017)

Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
por: Ocker, Matthias
Publicado: (2020)

Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: A review
por: Almeida, Naiade Silveira, et al.
Publicado: (2018)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
por: Skat‐Rørdam, Josephine, et al.
Publicado: (2019)

Hepatocyte transplantation: Consider infusion before incision
por: Heath, Ryan D, et al.
Publicado: (2017)

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article
por: Chao, Che-Yung, et al.
Publicado: (2016)

Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis
por: Leoni, Simona, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease and Atherosclerosis at a crossroad: The overlap of a theory of change and bioinformatics
por: Trovato, Guglielmo M
Publicado: (2020)

Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence
por: Anirvan, Prajna, et al.
Publicado: (2021)

Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals
por: Bilic-Curcic, Ines, et al.
Publicado: (2021)

Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
por: Wibawa, I Dewa Nyoman, et al.
Publicado: (2023)

Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?
por: Baratta, Francesco, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
por: Mandour, Mandour Omer, et al.
Publicado: (2022)

Liver in the limelight in the corona (COVID-19) time
por: Chela, Harleen Kaur, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach
por: Perez-Carreras, Mercedes, et al.
Publicado: (2021)

Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence
por: Jeyakumar, Shanmugam Murugaiha, et al.
Publicado: (2022)

Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
por: Abu Khalaf, Suha, et al.
Publicado: (2020)

Mediterranean diet and nonalcoholic fatty liver disease
por: Anania, Caterina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i47dm0q3s6j2e3bsgg6a1pdc9i